NEW DELHI, Oct. 12 (Xinhua) -- India's subject expert committee (SEC) has recommended Bharat Biotech's COVID-19 vaccine - Covaxin for use on children in the 2-18 age group, local media reported Tuesday.
The SEC has sent recommendations to the Drugs Controller General of India (DCGI), which has the authority to give final approval.
"The Hyderabad-based Bharat Biotech had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the DCGI at the start of this month," a local media report said.
If Covaxin gets approval, it will be the second vaccine cleared for use on children in India. In August, Zydus Cadila's three-dose DNA jab was allowed to be used on adults and children over 12 years old.
India is focussing on vaccinating children against the COVID-19.
At present, vaccination for people above 18 years is underway in the country. According to the federal health ministry, until Tuesday morning, over 958 million doses of the COVID-19 vaccine have been administered. Enditem
